NGIN
Next Generation HIV-1 Immunogens inducing broadly reactive Neutralising antibodies
| Coordinatore | UNIVERSITA VITA-SALUTE SAN RAFFAELE
Organization address
address: Via Olgettina 58 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 10˙148˙011 € |
| EC contributo | 7˙534˙742 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-IP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-02-01 - 2012-07-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITA VITA-SALUTE SAN RAFFAELE
Organization address
address: Via Olgettina 58 contact info |
IT (MILANO) | coordinator | 0.00 |
| 2 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | participant | 0.00 |
| 3 |
AVARIS AB
Organization address
address: "C/O Karolisnka Innovations AB, Fogdevreten 2B" contact info |
SE (STOCKHOLM) | participant | 0.00 |
| 4 |
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Organization address
address: RUE LEBLANC 25 contact info |
FR (PARIS 15) | participant | 0.00 |
| 5 |
CYTOS BIOTECHLOLOGY AG
Organization address
address: "Waggistrasse, 25" contact info |
CH (ZURICH-SCHLIEREN) | participant | 0.00 |
| 6 |
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR
Organization address
address: Via Olgettina 60 contact info |
IT (MILANO) | participant | 0.00 |
| 7 |
HEALTH PROTECTION AGENCY HPA
Organization address
address: Central Office - 7th Floor, Holborn Gate - High Holborn 330 contact info |
UK (LONDON) | participant | 0.00 |
| 8 |
ISTITUTO NAZIONALE TUMORI Fondazione Pascale
Organization address
address: Via Mariano Semmola 142 contact info |
IT (NAPOLI) | participant | 0.00 |
| 9 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 0.00 |
| 10 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 0.00 |
| 11 |
MEDICAL RESEARCH COUNCIL
Organization address
address: NORTH STAR AVENUE POLARIS HOUSE contact info |
UK (SWINDON) | participant | 0.00 |
| 12 |
MYMETICS SA
Organization address
address: ROUTE DE LA CORNICHE 4 contact info |
CH (EPALINGES) | participant | 0.00 |
| 13 |
Ospedale San Raffaele
Organization address
address: Via Olgettina 60 contact info |
IT (Milano) | participant | 0.00 |
| 14 |
PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE
Organization address
address: Nationalestraat 155 contact info |
BE (ANTWERPEN) | participant | 0.00 |
| 15 |
STATENS SERUM INSTITUT
Organization address
address: ARTILLERIVEJ 5 contact info |
DK (KOBENHAVN S) | participant | 0.00 |
| 16 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 0.00 |
| 17 |
UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono 7 contact info |
IT (MILANO) | participant | 0.00 |
| 18 |
UNIVERSITE PARIS DESCARTES
Organization address
address: Rue de l'Ecole de Medecine 12 contact info |
FR (PARIS) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The elicitation of broadly neutralising antibodies (Nab) remains the primary and most challenging goal in HIV-1 vaccine development. Although a few anti-HIV-1 monoclonal antibodies with broadly neutralising capability have been isolated from infected individuals, none of the immunization strategies thus far explored has proven effective in inducing similar antibodies. Objective of this application is the development of a variety of ‘next-generation’ HIV-1 envelope-based immunogens that in combination with new adjuvant formulations are capable of eliciting high-titer broadly Nab responses. Our strategy will be based on one side on the identification and cloning of envelopes that have successfully elicited broad Nabs in their natural hosts, focusing on HIV-1 strains derived from patients with high-titered broad Nabs in their sera; on the other side, we will introduce rational modifications into these and promising HIV-env based immunogens that are already under development by NGIN’s partners, with the aim of exposing cryptic conserved neutralization epitopes and permitting their efficient presentation to the immune system. HIV-1 envelopes will be expressed in viral vectors or as trimeric (gp150) soluble proteins and screened for their immunogenicity and antigenicity in rabbits. A selection of envelopes with highest antigenicity will be expressed as trimeric envelope-complexes on the surface of virosomes or virus-like particles (VLP), to further improve immunogenicity. New immunogens will be evaluated in prime-boost regimens in rabbits using novel effective adjuvant formulations. Immunogen/adjuvant combinations that prove most effective in eliciting broadly Nabs both systemically and at the mucosal level will be evaluated in non-human primates for their immunogenicity and efficacy upon challenge with live heterologous virus. Finally, formulations that will elicit protective immunity in non-human primates will be forwarded for proof-of-principle testing in humans.'
Introduzione (Teaser)
A large European consortium is addressing the challenging issue of HIV vaccine development. Using novel HIV-1 envelope proteins as candidate antigens, they successfully demonstrated the generation of neutralising antibodies in rabbits and non-human primates.